OS THERAPIES INCORPORATED Effective Tax Rate
OS THERAPIES INCORPORATED (OSTX) reported Effective Tax Rate of 50.00% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateContinuingOperations · last filed 2026-08-14
- OS THERAPIES INCORPORATED effective income tax rate reconciliation, percent for the quarter ending 2026-03-31 was 50.00%, a 0.00% change year-over-year.
- OS THERAPIES INCORPORATED effective income tax rate reconciliation, percent for the quarter ending 2025-03-31 was 50.00%, a 0.00% change year-over-year.
- OS THERAPIES INCORPORATED effective income tax rate reconciliation, percent for the quarter ending 2024-03-31 was 50.00%.
- OS THERAPIES INCORPORATED effective income tax rate reconciliation, percent for fiscal 2025 was 50.00%, a 0.00% change from fiscal 2024.
- OS THERAPIES INCORPORATED effective income tax rate reconciliation, percent for fiscal 2024 was 50.00%.
| Period end | Effective Income Tax Rate Reconciliation, Percent 3 month | Effective Income Tax Rate Reconciliation, Percent 6 month | Effective Income Tax Rate Reconciliation, Percent 9 month | Effective Income Tax Rate Reconciliation, Percent 12 month |
|---|---|---|---|---|
| 2026-06-30 | 50.00% 10-Q · filed 2026-08-14 | |||
| 2026-03-31 | 50.00% 10-Q · filed 2026-05-18 | |||
| 2025-12-31 | 50.00% 10-K · filed 2026-03-31 | |||
| 2025-09-30 | 50.00% 10-Q · filed 2025-11-14 | |||
| 2025-06-30 | 50.00% 10-Q · filed 2025-08-18 | |||
| 2025-03-31 | 50.00% 10-Q · filed 2025-05-15 | |||
| 2024-12-31 | 50.00% 10-K · filed 2025-03-31 | |||
| 2024-09-30 | 50.00% 10-Q · filed 2024-11-15 | |||
| 2024-06-30 | 50.00% 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | 50.00% 10-Q · filed 2024-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |